Oxford BioMedica (OTCMKTS:OXBDF) Reaches New 52-Week High – Still a Buy?

Oxford BioMedica (OTCMKTS:OXBDFGet Free Report) hit a new 52-week high during trading on Thursday . The company traded as high as $11.72 and last traded at $11.72, with a volume of 1339 shares changing hands. The stock had previously closed at $9.9850.

Oxford BioMedica Price Performance

The stock has a fifty day moving average price of $8.60 and a two-hundred day moving average price of $7.47. The company has a current ratio of 1.89, a quick ratio of 1.67 and a debt-to-equity ratio of 3.08.

Oxford BioMedica Company Profile

(Get Free Report)

Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.

In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.

See Also

Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.